Published Date: 15 May 2024
Within the editorial "Therapeutic opportunities for hypermutated urothelial carcinomas beyond immunotherapy" published in Oncoscience, researcher Ioannis A. voutsadakis from Northern Ontario School of Medicine and Sault Area Hospital.
Read Full NewsFindings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation